VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 125 filers reported holding VERVE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.44 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,240,548 | -19.2% | 319,800 | +14.2% | 0.02% | -16.7% |
| Q2 2023 | $5,248,463 | +38.4% | 279,918 | +6.4% | 0.03% | +15.4% |
| Q1 2023 | $3,793,008 | -47.4% | 263,038 | -29.4% | 0.03% | -56.7% |
| Q4 2022 | $7,211,377 | +17.4% | 372,681 | +108.5% | 0.06% | -7.7% |
| Q3 2022 | $6,141,000 | +45.5% | 178,767 | -3.4% | 0.06% | +160.0% |
| Q1 2022 | $4,222,000 | -20.1% | 185,009 | +29.0% | 0.02% | -10.7% |
| Q4 2021 | $5,286,000 | – | 143,374 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |